Table 2.
Characteristics of the training and validation cohorts.
| Total (n = 65) | Training (n = 49) | Validation (n = 16) | p | |
|---|---|---|---|---|
| Sex | 0.596 | |||
| Male | 45 (69.2%) | 34 (69.4%) | 11 (68.8%) | |
| Female | 20 (30.8%) | 15 (30.6%) | 5 (31.3%) | |
|
| ||||
| Age, median (range) | 29.0 (8–72) | 29 (8–72) | 30 (16–54) | 0.703 |
|
| ||||
| Ann Arbor stage | 0.585 | |||
| I-II | 36 (55.4%) | 27 (55.1%) | 9 (56.3%) | |
| III-IV | 29 (44.6%) | 22 (44.9%) | 7 (43.8%) | |
|
| ||||
| Bulky disease | 0.678 | |||
| >10 cm | 9 (13.8%) | 6 (12.2%) | 3 (18.8%) | |
| <10 cm | 56 (86.2%) | 43 (87.8%) | 13 (81.3%) | |
|
| ||||
| BM | 0.612 | |||
| Yes | 9 (13.8%) | 7 (14.3%) | 2 (12.5%) | |
| No | 56 (86.2%) | 42 (85.7%) | 14 (87.5%) | |
|
| ||||
| Extranodal sites | 0.495 | |||
| Yes | 25 (38.5%) | 20 (40.8%) | 5 (31.3%) | |
| No | 40 (61.5%) | 29 (59.2%) | 11 (68.8%) | |
|
| ||||
| B symptoms | 0.389 | |||
| Yes | 22 (33.8%) | 18 (36.7%) | 4 (25.0%) | |
| No | 43 (66.2%) | 31 (63.3%) | 12 (75.0%) | |
|
| ||||
| Chemotherapy with IFRT | 0.565 | |||
| Yes | 4 (6.2%) | 4 (8.2%) | 0 (0.0%) | |
| No | 61 (93.8%) | 45 (91.8%) | 16 (100.0%) | |
LDH, lactate dehydrogenase, BM, bone marrow; IFRT, involved-field radiation therapy.